Aberrant DNA methylation in malignant melanoma
暂无分享,去创建一个
J. Sosman | J. Greally | A. Verma | Yongkai Mo | Yiting Yu | C. Schinke | Kathy Amiri
[1] Yao-Tseng Chen,et al. Cancer/testis (CT) antigens: Potential targets for immunotherapy , 2009, Cancer science.
[2] T. Deng,et al. An essential role for DNA methyltransferase 3a in melanoma tumorigenesis. , 2009, Biochemical and biophysical research communications.
[3] S. Ariyan,et al. Genome-wide screen of promoter methylation identifies novel markers in melanoma. , 2009, Genome research.
[4] D. Morton,et al. CpG Island Methylator Phenotype Predicts Progression of Malignant Melanoma , 2009, Clinical Cancer Research.
[5] Michael Krauthammer,et al. Integrative Analysis of Epigenetic Modulation in Melanoma Cell Response to Decitabine: Clinical Implications , 2009, PloS one.
[6] O. Fodstad,et al. Identification of novel epigenetically modified genes in human melanoma via promoter methylation gene profiling , 2008, Pigment cell & melanoma research.
[7] D. Polsky,et al. Frequent p16-independent inactivation of p14ARF in human melanoma. , 2008, Journal of the National Cancer Institute.
[8] Guillermo Garcia-Manero,et al. Evolution of decitabine development , 2008, Cancer.
[9] E. Borden,et al. Reversal of methylation silencing of Apo2L/TRAIL receptor 1 (DR4) expression overcomes resistance of SK-MEL-3 and SK-MEL-28 melanoma cells to interferons (IFNs) or Apo2L/TRAIL , 2008, Oncogene.
[10] P. Dupont,et al. Clinical response to the MAGE-A3 immunotherapeutic in metastatic melanoma patients is associated with a specific gene profile present prior to treatment , 2008 .
[11] P. Guldberg,et al. The genome and epigenome of malignant melanoma , 2007, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[12] H. Donninger,et al. The RASSF1A tumor suppressor , 2007, Journal of Cell Science.
[13] X. C. Xu. Tumor-suppressive activity of retinoic acid receptor-β in cancer , 2007 .
[14] Y. Miyagi,et al. Silencing of tissue factor pathway inhibitor‐2 gene in malignant melanomas , 2007, International journal of cancer.
[15] A. Bosserhoff,et al. Loss of maspin expression contributes to a more invasive potential in malignant melanoma. , 2007, Pigment cell research.
[16] A. Bosserhoff,et al. Epigenetic events in malignant melanoma. , 2007, Pigment cell research.
[17] Xìao-chun Xu. Tumor-suppressive activity of retinoic acid receptor-beta in cancer. , 2007, Cancer letters.
[18] M. Bosenberg,et al. Epigenetic silencing of novel tumor suppressors in malignant melanoma. , 2006, Cancer research.
[19] E. Borden,et al. Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] Kelly B. Moran,et al. Phase I Trial of Sequential Low-Dose 5-Aza-2′-Deoxycytidine Plus High-Dose Intravenous Bolus Interleukin-2 in Patients with Melanoma or Renal Cell Carcinoma , 2006, Clinical Cancer Research.
[21] Jian-Kang Zhu,et al. Role of the Arabidopsis DNA glycosylase/lyase ROS1 in active DNA demethylation. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[22] Alessandra Marini,et al. Epigenetic silencing of the PTEN gene in melanoma. , 2006, Cancer research.
[23] T. Ushijima,et al. Silencing of Peroxiredoxin 2 and aberrant methylation of 33 CpG islands in putative promoter regions in human malignant melanomas. , 2006, Cancer research.
[24] S. Ferrone,et al. Regulation of high molecular weight-melanoma associated antigen (HMW-MAA) gene expression by promoter DNA methylation in human melanoma cells , 2006, Oncogene.
[25] A. Mirmohammadsadegh,et al. Epigenetic inactivation of tumor suppressor genes in serum of patients with cutaneous melanoma. , 2006, The Journal of investigative dermatology.
[26] K. Niedojadło,et al. Apaf-1 expression in human cutaneous melanoma progression and in pigmented nevi. , 2006, Pigment cell research.
[27] M. Millward,et al. Promoter hypermethylation of the O(6)-methylguanine DNA methyltransferase gene and microsatellite instability in metastatic melanoma. , 2006, The Journal of investigative dermatology.
[28] S. O’Day,et al. Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] J. Ajani,et al. Induction of cyclooxygenase-2 by benzo[a]pyrene diol epoxide through inhibition of retinoic acid receptor-β2 expression , 2005, Oncogene.
[30] S. Baylin,et al. DNA methylation and gene silencing in cancer , 2005, Nature Clinical Practice Oncology.
[31] B. Ng,et al. The RASSF1A Isoform of RASSF1 Promotes Microtubule Stability and Suppresses Tumorigenesis , 2005, Molecular and Cellular Biology.
[32] Lloyd J. Old,et al. Cancer/testis antigens, gametogenesis and cancer , 2005, Nature Reviews Cancer.
[33] Robert Brown,et al. Multiple markers for melanoma progression regulated by DNA methylation: insights from transcriptomic studies. , 2005, Carcinogenesis.
[34] David A Jones,et al. Evaluation of a 7-day continuous intravenous infusion of decitabine: inhibition of promoter-specific and global genomic DNA methylation. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] A. Levine,et al. The p53 pathway: positive and negative feedback loops , 2005, Oncogene.
[36] M. Ueda,et al. Decreased expression of Apaf-1 with progression of melanoma. , 2005, Pigment cell research.
[37] A. Hardy. Mortality , 2005, The Lancet.
[38] M. You,et al. Tumor susceptibility of Rassf1a knockout mice. , 2005, Cancer research.
[39] C. Rödel,et al. What is the role of radiotherapy in bladder-preserving cancer therapy? , 2005, Nature Clinical Practice Oncology.
[40] T. Sugimura,et al. Promoter methylation profiling of 30 genes in human malignant melanoma , 2004, Cancer science.
[41] Yuhei Yamamoto,et al. Epigenetic silencing of E- and P-cadherin gene expression in human melanoma cell lines. , 2004, International journal of oncology.
[42] J. Cheng,et al. Deregulated Akt3 Activity Promotes Development of Malignant Melanoma , 2004, Cancer Research.
[43] Mark Shackleton,et al. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[44] P. Guldberg,et al. Genetic and epigenetic alterations of the APC gene in malignant melanoma , 2004, Oncogene.
[45] T. Boon,et al. Promoter-Dependent Mechanism Leading to Selective Hypomethylation within the 5′ Region of Gene MAGE-A1 in Tumor Cells , 2004, Molecular and Cellular Biology.
[46] D. Morton,et al. Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients , 2004, Oncogene.
[47] A. Feinberg,et al. The history of cancer epigenetics , 2004, Nature Reviews Cancer.
[48] G. Schwartsmann,et al. A Phase I Trial of Cisplatin Plus Decitabine, a New DNA-Hypomethylating Agent, in Patients with Advanced Solid Tumors and a Follow-Up Early Phase II Evaluation in Patients with Inoperable Non-Small Cell Lung Cancer , 2000, Investigational New Drugs.
[49] David A Jones,et al. Limited gene activation in tumor and normal epithelial cells treated with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine. , 2004, Molecular pharmacology.
[50] S. Pavey,et al. Expression profiling reveals that methylation of TIMP3 is involved in uveal melanoma development. , 2004, International journal of cancer.
[51] J. Herman,et al. Gene silencing in cancer in association with promoter hypermethylation. , 2003, The New England journal of medicine.
[52] T. Saida,et al. ASC/TMS1, a caspase‐1 activating adaptor, is downregulated by aberrant metylation in human melanoma , 2003, International journal of cancer.
[53] A. Bosserhoff,et al. Characterization of methylthioadenosin phosphorylase (MTAP) expression in malignant melanoma. , 2003, The American journal of pathology.
[54] A. Chan,et al. Hypermethylation of the tumor suppressor gene RASSFIA and frequent concomitant loss of heterozygosity at 3p21 in cervical cancers , 2003, International journal of cancer.
[55] G. Robertson,et al. Loss of PTEN promotes tumor development in malignant melanoma. , 2003, Cancer research.
[56] A. Chan,et al. Frequent hypermethylation of promoter region of RASSF1A in tumor tissues and voided urine of urinary bladder cancer patients , 2003, International journal of cancer.
[57] R. Jaenisch,et al. Chromosomal Instability and Tumors Promoted by DNA Hypomethylation , 2003, Science.
[58] G. Pfeifer,et al. Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma. , 2003, Cancer research.
[59] J. Herman,et al. A systematic profile of DNA methylation in human cancer cell lines. , 2003, Cancer research.
[60] P. Laird,et al. Phase I trial of continuous infusion 5-aza-2′-deoxycytidine , 2003, Cancer Chemotherapy and Pharmacology.
[61] Rachel Jones,et al. Behavioural genetics: Worms gang up on bacteria , 2002, Nature Reviews Genetics.
[62] E. Eisenhauer,et al. DNA methyltransferase inhibitors-state of the art. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[63] David Polsky,et al. Focus on melanoma. , 2002, Cancer cell.
[64] J. Minna,et al. Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[65] Peter A. Jones,et al. The fundamental role of epigenetic events in cancer , 2002, Nature Reviews Genetics.
[66] P. Laird,et al. DNA Methyltransferase Deficiency Modifies Cancer Susceptibility in Mice Lacking DNA Mismatch Repair , 2002, Molecular and Cellular Biology.
[67] A. Bird. DNA methylation patterns and epigenetic memory. , 2002, Genes & development.
[68] U. Weidle,et al. Expression profile of genes coding for melanoma differentiation antigens and cancer/testis antigens in metastatic lesions of human cutaneous melanoma , 2001, Melanoma research.
[69] L. Aaltonen,et al. Age-related hypermethylation of the 5' region of MLH1 in normal colonic mucosa is associated with microsatellite-unstable colorectal cancer development. , 2001, Cancer research.
[70] S. Fulda,et al. Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer , 2001, Oncogene.
[71] N. Gruis,et al. Promoter hypermethylation: a common cause of reduced p16(INK4a) expression in uveal melanoma. , 2001, Cancer research.
[72] Keith D Robertson,et al. DNA methylation, methyltransferases, and cancer , 2001, Oncogene.
[73] T. Kouzarides,et al. Dnmt3a binds deacetylases and is recruited by a sequence‐specific repressor to silence transcription , 2001, The EMBO journal.
[74] J. Issa,et al. Changes in DNA Methylation in Neoplasia: Pathophysiology and Therapeutic Implications , 2001, Annals of Internal Medicine.
[75] J. Minna,et al. Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours , 2001, Oncogene.
[76] J. Pablos. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma , 2001 .
[77] P. Jones,et al. Cancer: Death and methylation , 2001, Nature.
[78] T. Bestor,et al. The DNA methyltransferases of mammals. , 2000, Human molecular genetics.
[79] S. Baylin,et al. DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci , 2000, Nature Genetics.
[80] Chun Xing Li,et al. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3 , 2000, Nature Genetics.
[81] Peter L. Jones,et al. DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters , 2000, Nature Genetics.
[82] J. Herman,et al. CpG methylation is maintained in human cancer cells lacking DNMT1 , 2000, Nature.
[83] J. Herman,et al. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. , 2000, Trends in genetics : TIG.
[84] M. Lübbert,et al. Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[85] M. Tang,et al. Mutation hotspots and DNA methylation. , 2000, Current topics in microbiology and immunology.
[86] M. Lübbert,et al. DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: clinical results and possible mechanisms of action. , 2000, Current topics in microbiology and immunology.
[87] Luke Hughes-Davies,et al. DNA methyltransferase Dnmt1 associates with histone deacetylase activity , 2000, Nature Genetics.
[88] D. Haber,et al. DNA Methyltransferases Dnmt3a and Dnmt3b Are Essential for De Novo Methylation and Mammalian Development , 1999, Cell.
[89] R. Elashoff,et al. Prognostic significance of occult metastases detected by sentinel lymphadenectomy and reverse transcriptase-polymerase chain reaction in early-stage melanoma patients. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[90] S. Lowe,et al. Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition. , 1999, Science.
[91] J. Herman,et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[92] G. Walker,et al. Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets , 1998, Genes, chromosomes & cancer.
[93] Ken Chen,et al. The Ink4a Tumor Suppressor Gene Product, p19Arf, Interacts with MDM2 and Neutralizes MDM2's Inhibition of p53 , 1998, Cell.
[94] N. Hayward,et al. Low frequency of p16/CDKN2A methylation in sporadic melanoma: comparative approaches for methylation analysis of primary tumors. , 1997, Cancer research.
[95] L. Chin,et al. Cooperative effects of INK4a and ras in melanoma susceptibility in vivo. , 1997, Genes & development.
[96] K. Bélanger,et al. Pilot phase I-II study on 5-aza-2'-deoxycytidine (Decitabine) in patients with metastatic lung cancer. , 1997, Anti-cancer drugs.
[97] M. Loda,et al. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. , 1997, Cancer research.
[98] F. McCormick,et al. Signal transduction from multiple Ras effectors. , 1997, Current opinion in genetics & development.
[99] R. Kothary,et al. Lung tumors in mice expressing an antisense RARβ2 transgene , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[100] L. Chin,et al. Role of the INK4a Locus in Tumor Suppression and Cell Mortality , 1996, Cell.
[101] Rika Deraemaecker,et al. Expression of MAGE genes in primary and metastatic cutaneous melanoma , 1995, International journal of cancer.
[102] J. Herman,et al. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. , 1995, Cancer research.
[103] J S Lee,et al. Suppression of retinoic acid receptor-beta in premalignant oral lesions and its up-regulation by isotretinoin. , 1995, The New England journal of medicine.
[104] R. Jaenisch,et al. Toxicity of 5-aza-2'-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[105] B. Houle,et al. Tumor-suppressive effect of the retinoic acid receptor beta in human epidermoid lung cancer cells. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[106] V. Zagonel,et al. 5-Aza-2'-deoxycytidine (Decitabine) and 5-azacytidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes: past, present and future trends. , 1993, Leukemia.
[107] J C Briggs,et al. Cutaneous melanoma. , 1993, Journal of the American Academy of Dermatology.
[108] M. van Glabbeke,et al. The EORTC Early Clinical Trials Cooperative Group experience with 5-aza-2'-deoxycytidine (NSC 127716) in patients with colo-rectal, head and neck, renal carcinomas and malignant melanomas. , 1987, European journal of cancer & clinical oncology.
[109] G. Rivard,et al. Clinical trial on 5-aza-2'-deoxycytidine in patients with acute leukemia. , 1985, Pharmacology & therapeutics.
[110] M. N. Epstein,et al. A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. , 1984, Human pathology.
[111] R. Momparler,et al. Incorporation of 5-Aza-2'-deoxycytidine-5'-triphosphate into DNA. Interactions with mammalian DNA polymerase alpha and DNA methylase. , 1983, Molecular pharmacology.
[112] P. Barr,et al. On the mechanism of inhibition of DNA-cytosine methyltransferases by cytosine analogs , 1983, Cell.
[113] A. Feinberg,et al. Hypomethylation distinguishes genes of some human cancers from their normal counterparts , 1983, Nature.
[114] Kun-Tsan Lin,et al. Phase I study on 5-aza-2'-deoxycytidine in children with acute leukemia. , 1981, Leukemia research.
[115] Philip J. Farabaugh,et al. Molecular basis of base substitution hotspots in Escherichia coli , 1978, Nature.
[116] M. Rosenberg,et al. In situ hybridization of repetitive monkey genome sequences isolated from defective simian virus 40 DNA , 1976, Cell.
[117] U. G. Dailey. Cancer,Facts and Figures about. , 2022, Journal of the National Medical Association.